{"component": "definition", "props": {"groups": [{"samples": [{"hash": "89tqDaJfTJj", "uri": "/contracts/89tqDaJfTJj#additional-studies", "label": "Clinical Trial and Option Agreement (Asterias Biotherapeutics, Inc.)", "score": 25.0321697467, "published": true}, {"hash": "3ra3y05hXeo", "uri": "/contracts/3ra3y05hXeo#additional-studies", "label": "Clinical Trial and Option Agreement (Asterias Biotherapeutics, Inc.)", "score": 24.8569472964, "published": true}, {"hash": "cwEWptV5RaG", "uri": "/contracts/cwEWptV5RaG#additional-studies", "label": "Clinical Trial and Option Agreement (Biotime Inc)", "score": 24.848733744, "published": true}], "snippet_links": [{"key": "in-vitro", "type": "definition", "offset": [129, 137]}, {"key": "in-vivo-studies", "type": "clause", "offset": [141, 156]}, {"key": "after-the-effective-date", "type": "clause", "offset": [167, 191]}, {"key": "associated-with", "type": "definition", "offset": [196, 211]}, {"key": "the-product", "type": "clause", "offset": [224, 235]}, {"key": "clinical-trial", "type": "clause", "offset": [270, 284]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [295, 321]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [356, 374]}, {"key": "schedule-9", "type": "definition", "offset": [417, 427]}, {"key": "from-time-to-time", "type": "clause", "offset": [456, 473]}], "size": 5, "snippet": "means any biomarker, manufacturing, purity, toxicology, imaging or combination studies, or any other exploratory or pre-clinical in vitro or in vivo studies commenced after the Effective Date and associated with any part of the Product, or carried out in support of the clinical trial conducted pursuant to this Agreement, where such studies are performed by or on behalf of the Charity, including those described in Schedule 9 (as the same may be amended from time to time by the Charity).", "hash": "a35bc64a534b7d499b95472a1fccae92", "id": 1}, {"samples": [{"hash": "e7rGI7d7pxV", "uri": "/contracts/e7rGI7d7pxV#additional-studies", "label": "Exclusive License and Option Agreement", "score": 31.340862423, "published": true}, {"hash": "ilVo8UqONaQ", "uri": "/contracts/ilVo8UqONaQ#additional-studies", "label": "Exclusive License and Option Agreement (Mereo Biopharma Group PLC)", "score": 30.0650239562, "published": true}, {"hash": "eMfydQPJg0e", "uri": "/contracts/eMfydQPJg0e#additional-studies", "label": "Exclusive License and Option Agreement (Mereo Biopharma Group PLC)", "score": 29.2217659138, "published": true}], "snippet_links": [{"key": "research-agreements", "type": "definition", "offset": [30, 49]}, {"key": "each-case", "type": "definition", "offset": [151, 160]}, {"key": "relate-to", "type": "definition", "offset": [167, 176]}, {"key": "entered-into", "type": "clause", "offset": [209, 221]}, {"key": "prior-to", "type": "clause", "offset": [222, 230]}, {"key": "after-the-effective-date", "type": "clause", "offset": [234, 258]}, {"key": "section-56", "type": "clause", "offset": [271, 282]}, {"key": "part-1", "type": "clause", "offset": [308, 314]}], "size": 5, "snippet": "means the [***] collaborative research agreements currently under negotiation or recently executed between AstraZeneca or its Affiliates and [***], in each case which relate to the Compounds and which will be entered into prior to or after the Effective Date pursuant to Section 5.6, as further described in Part 1 of Schedule 1.3.", "hash": "d0de1ec1084fb8b973b2009c08754679", "id": 2}, {"samples": [{"hash": "teVg847Hyf", "uri": "/contracts/teVg847Hyf#additional-studies", "label": "Option and License Agreement (Aptose Biosciences Inc.)", "score": 30.3032169747, "published": true}, {"hash": "eUpik1HuzOx", "uri": "/contracts/eUpik1HuzOx#additional-studies", "label": "Option and License Agreement (Aptose Biosciences Inc.)", "score": 27.4339493498, "published": true}, {"hash": "bDmihL4FmMj", "uri": "/contracts/bDmihL4FmMj#additional-studies", "label": "Option and License Agreement", "score": 26.1704312115, "published": true}], "snippet_links": [{"key": "section-23", "type": "clause", "offset": [29, 40]}, {"key": "activities-during-evaluation-period", "type": "clause", "offset": [42, 77]}], "size": 3, "snippet": "has the meaning set forth in Section 2.3 (Activities During Evaluation Period).", "hash": "a98989bd710e5e3b0c5ea364a83c5e94", "id": 3}, {"samples": [{"hash": "kscJ3uR9ka8", "uri": "/contracts/kscJ3uR9ka8#additional-studies", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 29.848733744, "published": true}, {"hash": "fkR11Jpphyu", "uri": "/contracts/fkR11Jpphyu#additional-studies", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 29.1752224504, "published": true}, {"hash": "2HoW83qAfCL", "uri": "http://pdf.secdatabase.com/1961/0001144204-18-057990.pdf", "label": "pdf.secdatabase.com", "score": 18.1016635525, "published": false}], "snippet_links": [], "size": 3, "snippet": "means [***].", "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 4}, {"samples": [{"hash": "2e19qsgkKSP", "uri": "/contracts/2e19qsgkKSP#additional-studies", "label": "Clinical Trial and Option Agreement (Monopar Therapeutics)", "score": 29.2299794661, "published": true}, {"hash": "9yheuRvbCcb", "uri": "/contracts/9yheuRvbCcb#additional-studies", "label": "Clinical Trial and Option Agreement (Monopar Therapeutics)", "score": 28.9671457906, "published": true}, {"hash": "iaaMiaYDdhZ", "uri": "/contracts/iaaMiaYDdhZ#additional-studies", "label": "Clinical Trial and Option Agreement (Monopar Therapeutics)", "score": 28.8548939083, "published": true}], "snippet_links": [{"key": "in-vitro", "type": "definition", "offset": [129, 137]}, {"key": "in-vivo-studies", "type": "clause", "offset": [141, 156]}, {"key": "after-the-commencement-date", "type": "clause", "offset": [167, 194]}, {"key": "associated-with", "type": "definition", "offset": [199, 214]}, {"key": "clinical-trial", "type": "clause", "offset": [274, 288]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [299, 325]}, {"key": "by-or-on-behalf-of", "type": "definition", "offset": [360, 378]}, {"key": "from-time-to-time", "type": "clause", "offset": [419, 436]}], "size": 3, "snippet": "means any biomarker, manufacturing, purity, toxicology, imaging or combination studies, or any other exploratory or pre-clinical in vitro or in vivo studies commenced after the Commencement Date and associated with any part of the Antibody, or carried out in support of the clinical trial conducted pursuant to this Agreement, where such studies are performed by or on behalf of the Charity (as the same may be amended from time to time by the Charity).", "hash": "b12629261a33ca0521994f1ff418362b", "id": 5}, {"samples": [{"hash": "7EXucjna12V", "uri": "/contracts/7EXucjna12V#additional-studies", "label": "Co Development and License Agreement (Cell Therapeutics Inc)", "score": 22.3141683778, "published": true}, {"hash": "4neMe7nDRic", "uri": "http://investors.ctibiopharma.com/static-files/7a001e84-ab15-47b2-b75e-2a9224d82043", "label": "investors.ctibiopharma.com", "score": 9.9637234771, "published": false}, {"hash": "iStkETmj8Uv", "uri": "https://cbc.gcs-web.com/static-files/7a001e84-ab15-47b2-b75e-2a9224d82043", "label": "cbc.gcs-web.com", "score": 9.7980835044, "published": false}], "snippet_links": [{"key": "ongoing-studies", "type": "definition", "offset": [32, 47]}, {"key": "licensed-territory", "type": "definition", "offset": [49, 67]}, {"key": "territory-specific-study", "type": "definition", "offset": [182, 206]}, {"key": "agreed-to", "type": "definition", "offset": [207, 216]}, {"key": "by-the-parties", "type": "clause", "offset": [230, 244]}, {"key": "the-development-plan", "type": "clause", "offset": [256, 276]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [287, 325]}], "size": 3, "snippet": "means, other than the Currently Ongoing Studies, Licensed Territory Specific Studies, Extraterritorial Studies, and studies that can be both an Extraterritorial Study and a Licensed Territory Specific Study agreed to be conducted by the Parties as part of the Development Plan under the terms and conditions of this Agreement.", "hash": "ae0442618ab54351328b84d7ce7b26f6", "id": 6}, {"samples": [{"hash": "knnTGZxXcjU", "uri": "/contracts/knnTGZxXcjU#additional-studies", "label": "Exclusive License and Co Funding Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 33.3531827515, "published": true}, {"hash": "gJkqSQ4FY5c", "uri": "https://ir.arrowheadpharma.com/static-files/a7d56003-adcd-401b-a44d-233172626651", "label": "ir.arrowheadpharma.com", "score": 11.1765913758, "published": false}], "snippet_links": [{"key": "a-phase", "type": "definition", "offset": [25, 32]}, {"key": "treatment-of", "type": "definition", "offset": [89, 101]}, {"key": "phase-iii-clinical-trials", "type": "definition", "offset": [190, 215]}, {"key": "pediatric-patients", "type": "definition", "offset": [267, 285]}, {"key": "approval-of", "type": "definition", "offset": [414, 425]}, {"key": "the-co", "type": "clause", "offset": [525, 531]}, {"key": "development-plan", "type": "definition", "offset": [539, 555]}, {"key": "for-clarity", "type": "clause", "offset": [557, 568]}, {"key": "by-takeda", "type": "clause", "offset": [596, 605]}, {"key": "additional-study", "type": "definition", "offset": [612, 628]}], "size": 2, "snippet": "means, collectively, (a) a Phase III Clinical Trial for a Product that is focused on the treatment of cirrhotic patients (adult F4cc) conducted in or for the Profit-Share Territory, (b) any Phase III Clinical Trials for a Product that are focused on the treatment of pediatric patients conducted in or for the Profit-Share Territory, and (c) any other Clinical Trial that (i) is intended to support the Regulatory Approval of a Product for the treatment of cirrhotic patients or pediatric patients and (ii) is included under the Co-Funded Development Plan. For clarity, the [***] to be performed by Takeda is an Additional Study.", "hash": "7d0dc6568e6f14054d01d452674f9358", "id": 7}, {"samples": [{"hash": "a0SJ2FRRvQf", "uri": "/contracts/a0SJ2FRRvQf#additional-studies", "label": "Exclusive License and Co Funding Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 32.0937713895, "published": true}, {"hash": "iJ0Zx4usaJZ", "uri": "https://ir.arrowheadpharma.com/static-files/14c571db-cd97-4afe-af04-be9f5636b1c4", "label": "ir.arrowheadpharma.com", "score": 10.5468856947, "published": false}], "snippet_links": [{"key": "a-phase", "type": "definition", "offset": [25, 32]}, {"key": "treatment-of", "type": "definition", "offset": [89, 101]}, {"key": "phase-iii-clinical-trials", "type": "definition", "offset": [146, 171]}, {"key": "pediatric-patients", "type": "definition", "offset": [223, 241]}], "size": 2, "snippet": "means, collectively, (a) a Phase III Clinical Trial for a Product that is focused on the treatment of cirrhotic patients (adult F4cc) and (b) any Phase III Clinical Trials for a Product that are focused on the treatment of pediatric patients.", "hash": "0b01c4117b7f8ee6d61c0597f7493e38", "id": 8}, {"samples": [{"hash": "knnTGZxXcjU", "uri": "/contracts/knnTGZxXcjU#additional-studies", "label": "Exclusive License and Co Funding Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 33.3531827515, "published": true}], "snippet_links": [{"key": "replaced-with", "type": "clause", "offset": [38, 51]}], "size": 1, "snippet": "is hereby deleted in its entirety and replaced with the following:", "hash": "88517e90c619aa43a19c166c9beb6285", "id": 9}, {"samples": [{"hash": "6erLNDAvHdz", "uri": "/contracts/6erLNDAvHdz#additional-studies", "label": "Option Agreement (Anthra Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-47", "type": "clause", "offset": [36, 47]}], "size": 1, "snippet": "shall have the meaning set forth in Section 4.7.", "hash": "926487f670b78c814a4c61202f379d4d", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbYWRkaXRpb25hbC1zdHVkaWVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Additional Studies", "size": 31, "snippet": "means any biomarker, manufacturing, purity, toxicology, imaging or combination studies, or any other exploratory or pre-clinical in vitro or in vivo studies commenced after the Effective Date and associated with any part of the Product, or carried out in support of the clinical trial conducted pursuant to this Agreement, where such studies are performed by or on behalf of the Charity, including those described in Schedule 9 (as the same may be amended from time to time by the Charity).", "id": "additional-studies", "examples": ["Each Party shall conduct the Internal SAV Programs, POC Programs, Additional Research Programs, Joint Development Programs and Independent <strong>Additional Studies</strong> and other activities under the Internal SAV Program Plans, POC Plans, Additional Research Plans, Joint Development Plan and Budget for the applicable Program or Independent Additional Study Development Plans in compliance with all applicable Laws.", "Each Party will maintain, or cause to be maintained, records of its activities under the Additional Research Programs, Joint Development Programs and Independent <strong>Additional Studies</strong> (as applicable) in sufficient detail and in good scientific manner appropriate for scientific, Patent and regulatory purposes, that will properly reflect all work performed therein, for a period consistent with such Party\u2019s record retention policies, but in no event less than required by applicable Laws.", "For clarity, for JDC-approved <strong>Additional Studies</strong> proposed by Receptos, it is expected that Receptos shall have significant participation rights and responsibility for such <strong>Additional Studies</strong> [to be enumerated in the definitive agreement].", "As of the Execution Date, Aptose has received an additional fifteen grams (15g) of CG\u2019806 (the \u201cAdditional Materials\u201d) to conduct the <strong>Additional Studies</strong>.", "Astellas shall pay any non-disputed amounts set forth on such <strong>Additional Studies</strong> invoices within [**] following Astellas\u2019 receipt of the applicable invoice.", "The non-IAS Party shall provide other information and assistance as the IAS Party may reasonably request in connection with the completion of and submission of INDs or CTAs for Independent <strong>Additional Studies</strong> for such Program; provided, however, Moderna shall have no right to directly access the CMC data for [***].", "Without limiting the foregoing, the Parties agree to grant each other such Rights of Reference as are necessary, and to otherwise cooperate in good faith, to enable the conduct of Independent <strong>Additional Studies</strong> in accordance with the terms of this Agreement, including to with respect to submission of Regulatory Filings, applications for Regulatory Approvals and the maintenance thereof.", "Astellas may withhold from payment any amount disputed by Astellas in good faith, pending resolution of the dispute and Pandion shall continue performing its obligations for any uncompleted or ongoing <strong>Additional Studies</strong> in accordance with this Agreement notwithstanding any such dispute or actual or alleged nonpayment that is the subject of the dispute, pending its resolution.", "Any additional costs and/or expenses to complete the <strong>Additional Studies</strong> beyond the budget approved by Astellas shall be borne by Pandion.", "The Trustee shall be liable for the safekeeping and administration of the Trust Account Assets in accordance with provisions of this Section 2.3."], "related": [["additional-sdu-study", "Additional SDU Study", "Additional SDU Study"], ["clinical-studies", "Clinical Studies", "Clinical Studies"], ["phase-iii-clinical-study", "Phase III Clinical Study", "Phase III Clinical Study"], ["phase-i-clinical-study", "Phase I Clinical Study", "Phase I Clinical Study"], ["development-candidate", "Development Candidate", "Development Candidate"]], "related_snippets": [], "updated": "2025-07-06T21:58:29+00:00"}, "json": true, "cursor": ""}}